These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 8548952)
21. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Reiners C; Dietlein M; Luster M Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):989-1007. PubMed ID: 19041827 [TBL] [Abstract][Full Text] [Related]
22. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments. Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937 [TBL] [Abstract][Full Text] [Related]
23. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer. Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714 [TBL] [Abstract][Full Text] [Related]
24. Chronic myeloid leukemia in a woman with papillary carcinoma of the thyroid treated with radioactive iodine. Alfiar F; Amato D; Lipton JH Leuk Lymphoma; 1997 Oct; 27(3-4):365-7. PubMed ID: 9402335 [TBL] [Abstract][Full Text] [Related]
25. The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma. Pelikan DM; Lion HL; Hermans J; Goslings BM Clin Endocrinol (Oxf); 1997 Dec; 47(6):713-20. PubMed ID: 9497879 [TBL] [Abstract][Full Text] [Related]
36. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer. Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198 [TBL] [Abstract][Full Text] [Related]
37. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Pluijmen MJ; Eustatia-Rutten C; Goslings BM; Stokkel MP; Arias AM; Diamant M; Romijn JA; Smit JW Clin Endocrinol (Oxf); 2003 Apr; 58(4):428-35. PubMed ID: 12641625 [TBL] [Abstract][Full Text] [Related]
38. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma. Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785 [TBL] [Abstract][Full Text] [Related]
39. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. Lin JD; Kao PF; Chao TC Br J Radiol; 1998 Mar; 71(843):307-13. PubMed ID: 9616241 [TBL] [Abstract][Full Text] [Related]
40. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]